Declared Dividend • May 14
Dividend of CN¥0.30 announced Shareholders will receive a dividend of CN¥0.30. Ex-date: 19th May 2026 Payment date: 19th May 2026 Dividend yield will be 2.9%, which is higher than the industry average of 2.2%. Sustainability & Growth Dividend is covered by earnings (13% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has increased by an average of 11% per year over the past 10 years. However, payments have been volatile during that time. Earnings per share has grown by 21% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Reported Earnings • Apr 22
First quarter 2026 earnings released: EPS: CN¥0.43 (vs CN¥0.13 in 1Q 2025) First quarter 2026 results: EPS: CN¥0.43 (up from CN¥0.13 in 1Q 2025). Revenue: CN¥602.0m (up 27% from 1Q 2025). Net income: CN¥162.7m (up 238% from 1Q 2025). Profit margin: 27% (up from 10% in 1Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 18% per year. Announcement • Mar 31
Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Q1, 2026 Results on Apr 22, 2026 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that they will report Q1, 2026 results on Apr 22, 2026 Valuation Update With 7 Day Price Move • Mar 27
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to CN¥15.72, the stock trades at a trailing P/E ratio of 17.6x. Average trailing P/E is 32x in the Food industry in China. Total returns to shareholders of 106% over the past three years. Reported Earnings • Mar 21
Full year 2025 earnings released: EPS: CN¥0.89 (vs CN¥0.33 in FY 2024) Full year 2025 results: EPS: CN¥0.89 (up from CN¥0.33 in FY 2024). Revenue: CN¥2.10b (up 8.4% from FY 2024). Net income: CN¥335.0m (up 162% from FY 2024). Profit margin: 16% (up from 6.6% in FY 2024). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 30% per year, which means it is well ahead of earnings. Announcement • Mar 20
Tianshui Zhongxing Bio-technology Co.,Ltd., Annual General Meeting, Apr 15, 2026 Tianshui Zhongxing Bio-technology Co.,Ltd., Annual General Meeting, Apr 15, 2026, at 14:30 China Standard Time. Location: The Company's Meeting Room, Tianshui, Gansu China Announcement • Jan 22
Tianshui Zhongxing Bio-technology Co.,Ltd. Approves Cash Dividend for Third Quarter of 2025 Tianshui Zhongxing Bio-technology Co.,Ltd. at its Extraordinary General Meeting held on January 20, 2026 approved a cash dividend of CNY 1.50000000 per 10 shares (tax included) for the third quarter of 2025. Announcement • Dec 31
Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Fiscal Year 2025 Results on Mar 21, 2026 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that they will report fiscal year 2025 results on Mar 21, 2026 Valuation Update With 7 Day Price Move • Dec 19
Investor sentiment improves as stock rises 18% After last week's 18% share price gain to CN¥14.66, the stock trades at a trailing P/E ratio of 22.5x. Average trailing P/E is 33x in the Food industry in China. Total returns to shareholders of 100% over the past three years. Valuation Update With 7 Day Price Move • Nov 03
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to CN¥14.37, the stock trades at a trailing P/E ratio of 22.1x. Average trailing P/E is 34x in the Food industry in China. Total returns to shareholders of 95% over the past three years. Reported Earnings • Oct 28
Third quarter 2025 earnings released: EPS: CN¥0.36 (vs CN¥0.15 in 3Q 2024) Third quarter 2025 results: EPS: CN¥0.36 (up from CN¥0.15 in 3Q 2024). Revenue: CN¥567.5m (up 13% from 3Q 2024). Net income: CN¥135.3m (up 129% from 3Q 2024). Profit margin: 24% (up from 12% in 3Q 2024). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has increased by 16% per year, which means it is well ahead of earnings. New Risk • Oct 28
New minor risk - Dividend sustainability The dividend is not well covered by cash flows. Dividend per share is over 81x cash flows per share. Dividend yield: 2.3% This is considered a minor risk. Dividends are ultimately paid out of the company's available cash reserves. Companies that pay out too much of their cash flow are at risk of having to reduce or cut their dividend in future. If cash flow growth slows or cash flows fall, then there may not be enough cash reserves to maintain the same dividend. Or in extreme cases, companies may opt to take on debt to maintain the dividend. This risk is mitigated by the fact the dividend is covered by earnings, however, cash flows are generally more important. For dividend paying companies, any reduction in the dividend can significantly impact the share price. This is currently the only risk that has been identified for the company. Announcement • Sep 30
Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Q3, 2025 Results on Oct 28, 2025 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that they will report Q3, 2025 results on Oct 28, 2025 Valuation Update With 7 Day Price Move • Sep 12
Investor sentiment improves as stock rises 27% After last week's 27% share price gain to CN¥10.09, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 31x in the Food industry in China. Total returns to shareholders of 59% over the past three years. Buy Or Sell Opportunity • Sep 11
Now 28% overvalued after recent price rise Over the last 90 days, the stock has risen 14% to CN¥9.17. The fair value is estimated to be CN¥7.16, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable. Reported Earnings • Aug 19
Second quarter 2025 earnings released: EPS: CN¥0.056 (vs CN¥0.013 loss in 2Q 2024) Second quarter 2025 results: EPS: CN¥0.056 (up from CN¥0.013 loss in 2Q 2024). Revenue: CN¥435.2m (up 1.7% from 2Q 2024). Net income: CN¥20.8m (up CN¥26.1m from 2Q 2024). Profit margin: 4.8% (up from net loss in 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Announcement • Jul 02
Tianshui Zhongxing Bio-technology Co.,Ltd. to Report First Half, 2025 Results on Aug 16, 2025 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that they will report first half, 2025 results on Aug 16, 2025 Declared Dividend • May 14
Dividend of CN¥0.30 announced Dividend of CN¥0.30 is the same as last year. Ex-date: 19th May 2025 Payment date: 19th May 2025 Dividend yield will be 3.8%, which is higher than the industry average of 2.2%. Sustainability & Growth Dividend is covered by both earnings (82% earnings payout ratio) and cash flows (42% cash payout ratio). The dividend has increased by an average of 21% per year over the past 9 years and payments have been stable during that time. Earnings per share has grown by 12% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Announcement • Apr 17
Tianshui Zhongxing Bio-technology Co.,Ltd. Approves Cash Dividend for the Year 2024 Tianshui Zhongxing Bio-technology Co.,Ltd. at its Annual General Meeting held on 15 April 2025, approved cash dividend of CNY 3.00000000 per 10 shares (tax included) for the year 2024. Announcement • Mar 31
Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Q1, 2025 Results on Apr 19, 2025 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that they will report Q1, 2025 results on Apr 19, 2025 New Risk • Mar 30
New minor risk - Earnings quality The company has large one-off items impacting its financial results. One-off items were 35% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Minor Risks Dividend is not well covered by earnings (92% payout ratio). Large one-off items impacting financial results. Announcement • Mar 26
Tianshui Zhongxing Bio-Technology Co.,Ltd. Proposes Final Dividend for the Year 2024 Tianshui Zhongxing Bio-technology Co.,Ltd. proposed final dividend of CNY 3.00000000 per 10 shares (tax included) for the year 2024. Announcement • Mar 24
Tianshui Zhongxing Bio-technology Co.,Ltd., Annual General Meeting, Apr 15, 2025 Tianshui Zhongxing Bio-technology Co.,Ltd., Annual General Meeting, Apr 15, 2025, at 14:30 China Standard Time. Location: The Company's Meeting Room, Tianshui, Gansu China Reported Earnings • Mar 22
Full year 2024 earnings released: EPS: CN¥0.33 (vs CN¥0.39 in FY 2023) Full year 2024 results: EPS: CN¥0.33 (down from CN¥0.39 in FY 2023). Revenue: CN¥1.94b (flat on FY 2023). Net income: CN¥128.0m (down 20% from FY 2023). Profit margin: 6.6% (down from 8.3% in FY 2023). Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 2% per year. Announcement • Dec 31
Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Fiscal Year 2024 Results on Mar 22, 2025 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that they will report fiscal year 2024 results on Mar 22, 2025 Reported Earnings • Oct 26
Third quarter 2024 earnings released: EPS: CN¥0.15 (vs CN¥0.056 loss in 3Q 2023) Third quarter 2024 results: EPS: CN¥0.15 (up from CN¥0.056 loss in 3Q 2023). Revenue: CN¥501.8m (up 16% from 3Q 2023). Net income: CN¥59.2m (up CN¥81.1m from 3Q 2023). Profit margin: 12% (up from net loss in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Q3, 2024 Results on Oct 26, 2024 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that they will report Q3, 2024 results on Oct 26, 2024 Reported Earnings • Aug 16
Second quarter 2024 earnings released: CN¥0.013 loss per share (vs CN¥0.002 loss in 2Q 2023) Second quarter 2024 results: CN¥0.013 loss per share (further deteriorated from CN¥0.002 loss in 2Q 2023). Revenue: CN¥428.0m (up 8.1% from 2Q 2023). Net loss: CN¥5.27m (loss widened CN¥4.64m from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Announcement • Jun 29
Tianshui Zhongxing Bio-technology Co.,Ltd. to Report First Half, 2024 Results on Aug 16, 2024 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that they will report first half, 2024 results on Aug 16, 2024 Declared Dividend • May 11
Dividend of CN¥0.30 announced Dividend of CN¥0.30 is the same as last year. Ex-date: 16th May 2024 Payment date: 16th May 2024 Dividend yield will be 4.0%, which is higher than the industry average of 2.2%. Sustainability & Growth Dividend is being paid despite the company being loss-making over the last 12 months. However, the dividend is covered by cash flows (65% cash payout ratio). The dividend has increased by an average of 24% per year over the past 8 years and payments have been stable during that time. Announcement • May 11
Tianshui Zhongxing Bio-technology Co.,Ltd. Announces Dividend Implementation of 2023 Final Profit Distribution, Payable on 16 May 2024 Tianshui Zhongxing Bio-technology Co.,Ltd. announced 2023 final profit distribution plan to be implemented (A shares): Cash dividend/10 shares (tax included): CNY 3.00000000. Record date: 15 May 2024; Ex-date: 16 May 2024; Payment date: 16 May 2024. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: CN¥0.088 (vs CN¥0.50 in 1Q 2023) First quarter 2024 results: EPS: CN¥0.088 (down from CN¥0.50 in 1Q 2023). Revenue: CN¥486.7m (down 22% from 1Q 2023). Net income: CN¥34.7m (down 83% from 1Q 2023). Profit margin: 7.1% (down from 32% in 1Q 2023). Over the last 3 years on average, earnings per share has increased by 19% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. Announcement • Mar 30
Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Q1, 2024 Results on Apr 26, 2024 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that they will report Q1, 2024 results on Apr 26, 2024 Announcement • Mar 26
Tianshui Zhongxing Bio-technology Co.,Ltd., Annual General Meeting, Apr 16, 2024 Tianshui Zhongxing Bio-technology Co.,Ltd., Annual General Meeting, Apr 16, 2024, at 14:30 China Standard Time. Location: The Company's Meeting Room, Tianshui, Gansu China Reported Earnings • Mar 26
Full year 2023 earnings released: EPS: CN¥0.39 (vs CN¥0.40 in FY 2022) Full year 2023 results: EPS: CN¥0.39. Revenue: CN¥1.93b (down 2.0% from FY 2022). Net income: CN¥159.6m (flat on FY 2022). Profit margin: 8.3% (up from 8.0% in FY 2022). The increase in margin was driven by lower expenses. Valuation Update With 7 Day Price Move • Mar 14
Investor sentiment improves as stock rises 19% After last week's 19% share price gain to CN¥7.95, the stock trades at a trailing P/E ratio of 14.5x. Average trailing P/E is 27x in the Food industry in China. Total loss to shareholders of 6.7% over the past three years. Valuation Update With 7 Day Price Move • Feb 02
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to CN¥6.39, the stock trades at a trailing P/E ratio of 11.7x. Average trailing P/E is 27x in the Food industry in China. Total loss to shareholders of 14% over the past three years. Announcement • Dec 29
Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that they will report fiscal year 2023 results on Mar 26, 2024 Reported Earnings • Nov 01
Third quarter 2023 earnings released: CN¥0.056 loss per share (vs CN¥0.36 profit in 3Q 2022) Third quarter 2023 results: CN¥0.056 loss per share (down from CN¥0.36 profit in 3Q 2022). Revenue: CN¥433.6m (down 26% from 3Q 2022). Net loss: CN¥21.9m (down 116% from profit in 3Q 2022). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 3% per year, which means it is significantly lagging earnings. Announcement • Sep 30
Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Q3, 2023 Results on Oct 28, 2023 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that they will report Q3, 2023 results on Oct 28, 2023 Reported Earnings • Aug 19
Second quarter 2023 earnings released: CN¥0.002 loss per share (vs CN¥0.088 loss in 2Q 2022) Second quarter 2023 results: CN¥0.002 loss per share (improved from CN¥0.088 loss in 2Q 2022). Revenue: CN¥395.9m (up 6.8% from 2Q 2022). Net loss: CN¥628.8k (loss narrowed 98% from 2Q 2022). Over the last 3 years on average, earnings per share has increased by 30% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Jul 01
Tianshui Zhongxing Bio-technology Co.,Ltd. to Report First Half, 2023 Results on Aug 19, 2023 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that they will report first half, 2023 results on Aug 19, 2023 Upcoming Dividend • May 02
Upcoming dividend of CN¥0.30 per share at 2.8% yield Eligible shareholders must have bought the stock before 09 May 2023. Payment date: 09 May 2023. Trailing yield: 2.8%. Within top quartile of Chinese dividend payers (2.0%). Higher than average of industry peers (1.6%). Valuation Update With 7 Day Price Move • Apr 11
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to CN¥10.58, the stock trades at a trailing P/E ratio of 32.6x. Average trailing P/E is 41x in the Food industry in China. Total returns to shareholders of 51% over the past three years. Reported Earnings • Mar 21
Full year 2022 earnings released: EPS: CN¥0.40 (vs CN¥0.14 in FY 2021) Full year 2022 results: EPS: CN¥0.40 (up from CN¥0.14 in FY 2021). Revenue: CN¥1.97b (up 27% from FY 2021). Net income: CN¥158.4m (up 188% from FY 2021). Profit margin: 8.0% (up from 3.5% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings. Board Change • Nov 16
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. 1 highly experienced director. 1 independent director (4 non-independent directors). GM & Director Liang Liu is the most experienced director on the board, commencing their role in 2012. Independent Director Ling Peng was the last independent director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. Valuation Update With 7 Day Price Move • Oct 18
Investor sentiment improved over the past week After last week's 25% share price gain to CN¥8.86, the stock trades at a trailing P/E ratio of 16.2x. Average trailing P/E is 39x in the Food industry in China. Total returns to shareholders of 33% over the past three years. Reported Earnings • Oct 12
Third quarter 2022 earnings released: EPS: CN¥0.36 (vs CN¥0.16 loss in 3Q 2021) Third quarter 2022 results: EPS: CN¥0.36 (up from CN¥0.16 loss in 3Q 2021). Revenue: CN¥586.1m (up 65% from 3Q 2021). Net income: CN¥138.4m (up CN¥199.9m from 3Q 2021). Profit margin: 24% (up from net loss in 3Q 2021). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 1% per year whereas the company’s share price has increased by 4% per year. Reported Earnings • Aug 21
Second quarter 2022 earnings released: CN¥0.088 loss per share (vs CN¥0.084 loss in 2Q 2021) Second quarter 2022 results: CN¥0.088 loss per share (down from CN¥0.084 loss in 2Q 2021). Revenue: CN¥370.6m (up 20% from 2Q 2021). Net loss: CN¥34.2m (loss widened 11% from 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. Announcement • May 13
Tianshui Zhongxing Bio-Technology Co.,Ltd. Announces 2021 Final Profit Distribution Plan, Payable on 19 May 2022 Tianshui Zhongxing Bio-technology Co.,Ltd. announced the 2021 final profit distribution plan of Cash dividend/10 A shares (tax included): CNY 1.00000000. The dividend will paid on 19 May 2022 with record date of 18 May 2022 and ex-date is 19 May 2022. 10% withholding tax on cash dividend will be deducted in CNY within the cash dividend receivable. Please refer to below details: Tax on cash dividend/10 shares: CNY 0.10000000 (10% x CNY 1.00000000). Net cash dividend/10 shares after tax: CNY 0.90000000 (CNY 1.00000000- CNY 0.10000000). Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 5 experienced directors. 7 highly experienced directors. 3 independent directors (6 non-independent directors). Chief Financial Officer, Deputy General Manager and Director Liang Liu was the last director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Apr 19
Tianshui Zhongxing Bio-technology Co.,Ltd. Approves Cash Dividend for 2021 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that at its Annual General Meeting held on 15 April 2022, approved cash dividend (tax included) of CNY 1.00000000 per 10 shares for 2021. Reported Earnings • Oct 26
Third quarter 2021 earnings released: CN¥0.16 loss per share (vs CN¥0.19 profit in 3Q 2020) The company reported a poor third quarter result with weaker earnings, revenues and control over costs. Third quarter 2021 results: Revenue: CN¥354.7m (down 11% from 3Q 2020). Net loss: CN¥61.5m (down 195% from profit in 3Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year whereas the company’s share price has increased by 6% per year. Valuation Update With 7 Day Price Move • Oct 19
Investor sentiment deteriorated over the past week After last week's 20% share price decline to CN¥8.24, the stock trades at a trailing P/E ratio of 23x. Average trailing P/E is 38x in the Food industry in China. Total returns to shareholders of 30% over the past three years. Valuation Update With 7 Day Price Move • Oct 04
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥10.12, the stock trades at a trailing P/E ratio of 28.3x. Average trailing P/E is 38x in the Food industry in China. Total returns to shareholders of 49% over the past three years. Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment improved over the past week After last week's 23% share price gain to CN¥13.78, the stock trades at a trailing P/E ratio of 32.6x. Average trailing P/E is 34x in the Food industry in China. Total returns to shareholders of 93% over the past three years. Reported Earnings • Aug 10
Second quarter 2021 earnings released: CN¥0.084 loss per share (vs CN¥0.054 loss in 2Q 2020) The company reported a soft second quarter result with increased losses and weaker control over costs, although revenues improved. Second quarter 2021 results: Revenue: CN¥308.6m (up 16% from 2Q 2020). Net loss: CN¥30.9m (loss widened 67% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 16% per year whereas the company’s share price has increased by 14% per year. Valuation Update With 7 Day Price Move • Jul 26
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥12.84, the stock trades at a trailing P/E ratio of 27.4x. Average trailing P/E is 35x in the Food industry in China. Total returns to shareholders of 66% over the past three years. Valuation Update With 7 Day Price Move • Jul 09
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥13.44, the stock trades at a trailing P/E ratio of 28.7x. Average trailing P/E is 37x in the Food industry in China. Total returns to shareholders of 64% over the past three years. Announcement • Jun 24
Tianshui Zhongxing Bio-technology Co.,Ltd. (SZSE:002772) signed a letter of intent to acquire Guizhou Moutai Shengjiao Wine Industry Co., Ltd. from Liu Liangyue. Tianshui Zhongxing Bio-technology Co.,Ltd. (SZSE:002772) signed a letter of intent to acquire Guizhou Moutai Shengjiao Wine Industry Co., Ltd. from Liu Liangyue on June 20, 2021. The consideration is paid in cash. Valuation Update With 7 Day Price Move • Jun 21
Investor sentiment improved over the past week After last week's 23% share price gain to CN¥9.64, the stock trades at a trailing P/E ratio of 20.6x. Average trailing P/E is 38x in the Food industry in China. Total returns to shareholders of 28% over the past three years. Reported Earnings • Apr 21
First quarter 2021 earnings released: EPS CN¥0.13 (vs CN¥0.22 in 1Q 2020) The company reported a soft first quarter result with weaker earnings and profit margins, although revenues improved. First quarter 2021 results: Revenue: CN¥395.8m (up 8.0% from 1Q 2020). Net income: CN¥43.4m (down 42% from 1Q 2020). Profit margin: 11% (down from 20% in 1Q 2020). Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Reported Earnings • Mar 26
Full year 2020 earnings released: EPS CN¥0.56 (vs CN¥0.19 in FY 2019) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2020 results: Revenue: CN¥1.48b (up 28% from FY 2019). Net income: CN¥189.0m (up 176% from FY 2019). Profit margin: 13% (up from 5.9% in FY 2019). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has fallen by 5% per year. Announcement • Feb 24
Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that they will report fiscal year 2020 results on Mar 26, 2021 Is New 90 Day High Low • Jan 27
New 90-day low: CN¥8.86 The company is down 4.0% from its price of CN¥9.20 on 29 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Food industry, which is up 23% over the same period. Valuation Update With 7 Day Price Move • Jan 14
Investor sentiment deteriorated over the past week After last week's 16% share price decline to CN¥9.03, the stock is trading at a trailing P/E ratio of 21.1x, down from the previous P/E ratio of 25.2x. This compares to an average P/E of 38x in the Food industry in China. Total return to shareholders over the past three years is a loss of 12%. Valuation Update With 7 Day Price Move • Jan 11
Investor sentiment deteriorated over the past week After last week's 15% share price decline to CN¥9.72, the stock is trading at a trailing P/E ratio of 22.7x, down from the previous P/E ratio of 26.8x. This compares to an average P/E of 40x in the Food industry in China. Total return to shareholders over the past three years is a loss of 4.8%. Valuation Update With 7 Day Price Move • Dec 31
Investor sentiment improved over the past week After last week's 22% share price gain to CN¥11.55, the stock is trading at a trailing P/E ratio of 27x, up from the previous P/E ratio of 22.2x. This compares to an average P/E of 39x in the Food industry in China. Total returns to shareholders over the past three years are 8.6%. Is New 90 Day High Low • Dec 30
New 90-day high: CN¥11.30 The company is up 24% from its price of CN¥9.10 on 30 September 2020. The Chinese market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Food industry, which is up 3.0% over the same period. Is New 90 Day High Low • Dec 07
New 90-day high: CN¥9.97 The company is up 8.0% from its price of CN¥9.24 on 08 September 2020. The Chinese market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Food industry, which is down 4.0% over the same period. Reported Earnings • Oct 23
Third quarter earnings released Over the last 12 months the company has reported total profits of CN¥149.6m, up 227% from the prior year. Total revenue was CN¥1.42b over the last 12 months, up 41% from the prior year. Announcement • Oct 16
Tianshui Zhongxing Bio-technology Co.,Ltd. to Report Q3, 2020 Results on Oct 22, 2020 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that they will report Q3, 2020 results on Oct 22, 2020 Announcement • Jul 31
Tianshui Zhongxing Bio-technology Co.,Ltd. to Report First Half, 2020 Results on Aug 22, 2020 Tianshui Zhongxing Bio-technology Co.,Ltd. announced that they will report first half, 2020 results on Aug 22, 2020